BioMed Research International / 2016 / Article / Tab 3

Research Article

Lack of Association between Genetic Polymorphisms of JAK-STAT Signaling Pathway Genes and Acute Anterior Uveitis in Han Chinese

Table 3

Allele and genotype frequencies in female AAU patients and female controls.

Gene
SNPAllele and genotypeAAU+AS+ (female)AAU+AS (female)Controls (female) (AS+)Pc (AS+)OR (95% CI) (AS)Pc (AS)OR (95% CI)

JAK1rs310241C80 (33.3%)138 (29.6%)156 (28.7%)0.19NS1.24 (0.90–1.72)0.74NS1.05 (0.80–1.37)
CC12 (10.0%)14 (6.0%)17 (6.2%)0.19NS1.67 (0.77–3.61)0.91NS0.96 (0.46–2.00)
CT56 (46.7%)110 (47.2%)122 (44.9%)0.74NS1.08 (0.70–1.66)0.60NS1.10 (0.77–1.56)
TT52 (43.3%)109 (46.8%)133 (48.9%)0.31NS0.80 (0.52–1.23)0.64NS0.92 (0.65–1.30)
rs2780815G159 (78.7%)400 (87.0%)495 (85.3%)0.03NS0.64 (0.42–0.96)0.45NS1.15 (0.80–1.63)
GG63 (62.4%)175 (76.1%)212 (73.1%)0.04NS0.61 (0.38–0.99)0.44NS1.17 (0.79–1.75)
GT33 (32.6%)50 (21.7%)71 (24.5%)0.11NS1.50 (0.91–2.45)0.46NS0.86 (0.57–1.29)
TT5 (5.0%)5 (2.2%)7 (2.4%)0.20NS2.11 (0.65–6.80)0.86NS0.90 (0.28–2.87)

JAK2rs10758669A170 (73.9%)328 (67.5%)399 (72.3%)0.64NS1.09 (0.77–1.54)0.10NS0.80 (0.61–1.04)
AA59 (51.3%)104 (42.8%)144 (52.2%)0.88NS0.97 (0.63–1.49)0.03NS0.69 (0.49–1.00)
AC52 (45.2%)120 (49.4%)111 (40.2%)0.36NS1.23 (0.79–1.90)0.04NS1.45 (1.02–2.05)
CC4 (3.5%)19 (7.8%)21 (7.6%)0.13NS0.44 (0.15–1.30)0.93NS1.03 (0.54–1.97)
rs10975003C44 (20.6%)117 (25.8%)93 (17.9%)0.40NS1.19 (0.80–1.77)2.83 × 10−30.091.59 (1.17–2.17)
CC2 (1.9%)11 (4.8%)8 (3.1%)0.52NS0.60 (0.13–2.87)0.32NS1.60 (0.63–4.06)
CT40 (37.4%)95 (41.9%)77 (29.6%)0.15NS1.42 (0.88–2.28)4.83 × 10−3NS1.71 (1.18–2.49)
TT65 (60.7%)121 (53.3%)175 (67.3%)0.23NS0.75 (0.47–1.20)1.59 × 10−30.0520.55 (0.38–0.80)

STAT1rs1547550C205 (86.9%)411 (88.6%)423 (87.0%)0.95NS0.99 (0.62–1.56)0.47NS1.16 (0.78–1.71)
CC88 (74.6%)182 (78.4%)185 (76.1%)0.75NS0.92 (0.55–1.53)0.55NS1.14 (0.74–1.75)
CG29 (24.6%)47 (20.3%)53 (21.8%)0.56NS1.17 (0.70–1.96)0.68NS0.91 (0.59–1.42)
GG1 (0.8%)3 (1.3%)5 (2.1%)0.40NS0.41 (0.05–3.52)0.56NS0.65 (0.15–2.76)
rs2066802C46 (20.4%)81 (17.4%)113 (21.2%)0.80NS0.95 (0.65–1.40)0.13NS0.78 (0.57–1.08)
CC1 (0.9%)6 (2.6%)8 (3.0%)0.22NS0.29 (0.04–2.34)0.78NS0.86 (0.29–2.50)
CT44 (38.9%)69 (29.6%)97 (36.3%)0.63NS1.12 (0.71–1.76)0.11NS0.74 (0.51–1.07)
TT68 (60.2%)158 (67.8%)162 (60.7%)0.93NS0.98 (0.63–1.54)0.10NS1.37 (0.95–1.97)
rs6718902C132 (60.0%)259 (54.2%)308 (53.8%)0.12NS1.29 (0.94–1.76)0.91NS1.01 (0.79–1.29)
CC36 (32.7%)72 (30.1%)82 (28.7%)0.43NS1.21 (0.75–1.94)0.72NS1.07 (0.74–1.56)
CT60 (54.5%)115 (48.1%)144 (50.3%)0.45NS1.18 (0.76–1.84)0.61NS0.92 (0.65–1.29)
TT14 (12.7%)52 (21.8%)60 (21.0%)0.06NS0.55 (0.29–1.03)0.83NS1.05 (0.69–1.59)
rs10199181A51 (24.8%)117 (26.1%)148 (25.2%)0.91NS0.98 (0.68–1.41)0.73NS1.05 (0.79–1.39)
AA6 (5.8%)20 (8.9%)19 (6.5%)0.82NS0.90 (0.35–2.31)0.29NS1.42 (0.74–2.73)
AT39 (37.9%)77 (34.4%)110 (37.4%)0.94NS1.02 (0.64–1.62)0.48NS0.88 (0.61–1.26)
TT58 (56.3%)127 (56.7%)165 (56.1%)0.97NS1.01 (0.64–1.58)0.90NS1.02 (0.72–1.45)

IRF1rs2070721A86 (40.6%)154 (33.9%)216 (34.3%)0.10NS1.31 (0.95–1.80)0.90NS0.98 (0.76–1.27)
AA15 (14.2%)26 (11.5%)29 (9.2%)0.15NS1.63 (0.84–3.17)0.39NS1.28 (0.73–2.23)
AC56 (52.8%)102 (44.9%)158 (50.2%)0.63NS1.11 (0.72–1.73)0.23NS0.81 (0.58–1.14)
CC35 (33.0%)99 (43.6%)128 (40.6%)0.16NS0.72 (0.45–1.14)0.49NS1.13 (0.80–1.60)

NOS2rs2297518A52 (20.5%)69 (15.2%)74 (15.7%)0.10NS1.39 (0.94–2.05)0.84NS0.96 (0.68–1.38)
AA3 (2.4%)6 (2.6%)2 (0.8%)0.24NS2.83 (0.47–17.17)0.14NS3.18 (0.63–15.90)
AG46 (36.2%)57 (25.2%)70 (29.7%)0.20NS1.35 (0.85–2.13)0.27NS0.80 (0.53–1.20)
GG78 (61.4%)164 (72.2%)164 (69.5%)0.12NS0.70 (0.45–1.10)0.51NS1.14 (0.77–1.71)
rs4795067A173 (73.9%)369 (75.9%)439 (77.8%)0.24NS0.81 (0.57–1.15)0.46NS0.90 (0.67–1.20)
AA62 (53.0%)145 (59.7%)169 (59.9%)0.20NS0.75 (0.49–1.16)0.95NS0.99 (0.70–1.40)
AG49 (41.9%)79 (32.5%)101 (35.8%)0.26NS1.29 (0.83–2.01)0.43NS0.86 (0.60–1.24)
GG6 (5.1%)19 (7.8%)12 (4.3%)0.70NS1.22 (0.45–3.32)0.08NS1.91 (0.91–4.02)

OR = odds ratio; 95% CI = 95% confidence interval.
Pc = value adjusted by Bonferroni correction.